Aids 2020

Ias 2023, the 12th international aids society conference on hiv science, took place in brisbane, australia, and virtually, on 23-26 july 2023, with over 5,000 participants. Delegates heard that inner sydney had reduced new hiv acquisitions by 88%, meaning that it may be the first locality in the world to reach the un target to end aids as a public health threat by 2030. Reprieve, a study with global implications for cardiovascular disease prevention in people with hiv, showed that daily statin treatment reduced the risk of major cardiovascular events in people with hiv at low-to-moderate risk of cardiovascular events. And the conference heard details of the "geneva patient", the first person to achieve hiv remission after receiving a bone marrow transplant containing hiv-susceptible stem cells. The conference featured 30 oral abstract sessions organized into five tracks. The 32 invited-speaker sessions were made up of eight plenaries and 24 symposia. Three pre-meetings and 56 satellite sessions complemented the invited-speaker and abstract-driven programme. A total of 3,857 abstracts were submitted to Ias 2023, including 395 late-breaker abstracts. Ultimately, 1,571 abstracts were selected for presentation in sessions and the poster exhibition, an acceptance rate of 38%.

The corporate partnership programme (cpp) actively promotes and facilitates the meaningful engagement of industry and non-industry partners in the global hiv response. It achieves this through the establishment of partnerships, harnessing the power collaboration, initiative multi-stakeholder dialogues, and coordinating united efforts to address barriers across the hiv prevention, diagnosis, and care continuum. Through its usd 80,000 gold membership, gilead has actively participated in 2023 across the activities of the three cpp groups: (1) forum, convening and catalyzing multi-stakeholder dialogue between biomedical industry and non-industry on a broad range of hiv topics, (2) cure group, focusing and identifying avenues for biomedical industry and non-industry collaboration in hiv cure research and development, and (3) vaccine group, encouraging and facilitating the contribution of the biomedical industry and non-industry to address the complexities of hiv vaccine research and development